Tag Archives: Prof Olav Mella

Norwegian Rituximab studies update

Posted on 11/03/2017 by wames

Helse Bergen blog post, 29 Sep 29017: RituxME B-lymphocyte depletion using the anti-CD20 antibody rituximab (Mabthera®) in Myalgic Encephalopathy/Chronic Fatigue Syndrome (“RituxME”) ​RituxME is a multicentre study conducted in five study centres in Norway: the Oncology Department at Haukeland University … Continue reading →

Posted in News | Tagged , , , , , | Comments Off on Norwegian Rituximab studies update

Fuel shortage: Norwegian study expands on energy problem in ME/CFS

Posted on 01/09/2017 by wames

Health rising blog post, by Cort Johnson, 27 Dec 2016: Fuel shortage: Norwegian study Expands on Energy Problem in Chronic Fatigue Syndrome (ME/CFS) Fluge and Mella seem to be working at almost lightning speed. Besides managing their huge Rituximab study … Continue reading →

Posted in News | Tagged , , , , , , | Comments Off on Fuel shortage: Norwegian study expands on energy problem in ME/CFS

Metabolic profiling indicates impaired pyruvate dehydrogenase function in ME/CFS

Posted on 12/23/2016 by wames

Research abstract: Myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) is a debilitating disease of unknown etiology, with hallmark symptoms including postexertional malaise and poor recovery. Metabolic dysfunction is a plausible contributing factor. We hypothesized that changes in serum amino acids may disclose … Continue reading →

Posted in News | Tagged , , , , , , | Comments Off on Metabolic profiling indicates impaired pyruvate dehydrogenase function in ME/CFS

Mella finds hypometabolic state in ME/CFS

Posted on 10/17/2016 by wames

Health rising blog post, by Cort Johnson, 15 October 2016: Another Hypometabolic Signature Found Fluge and Mella are best known for their Rituximab work, but just last week Mella reported that they’d found a hypometabolic state in ME/CFS as well. … Continue reading →

Posted in News | Tagged , , , , , , , , , | Comments Off on Mella finds hypometabolic state in ME/CFS

New rituximab trial results from Norway

Posted on 08/22/2016 by wames

Research abstract: Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We have previously suggested clinical benefit from B-cell depletion using the monoclonal anti-CD20 antibody rituximab in a randomized and placebo-controlled study. Prolonged responses were then demonstrated in … Continue reading →

Posted in News | Tagged , , , , , | Comments Off on New rituximab trial results from Norway

Cancer doctor Dagfinn Øgreid has treated ME patients with rituximab

Posted on 11/26/2015 by wames

Blog article: Offers private ME treatment with cancer drugs – scientists react, by Anne Grete Storvik, Nov 23 2015 in Dagensmedicin [ translated by Google translate] A private clinic in Sandnes offers treatment for ME with the cancer drug rituximab. Patients pay … Continue reading →

Posted in News | Tagged , , , , , , | 1 Comment

UK rituximab trial fundraising total almost reached

Posted on 09/28/2015 by wames

Invest in ME has announced the latest fundraising total for the rituximab/B-cell research, which is a great boost as the research team at UCL are about to visit and discuss the subject with Dr Fluge and Professor Mella in Haukeland University Hospital, … Continue reading →

Posted in News | Tagged , , , , , , , | Comments Off on UK rituximab trial fundraising total almost reached

Elevated autoantibodies found in CFS subgroup

Posted on 09/28/2015 by wames

Research highlights: β adrenergic and muscarinic acetylcholine receptor autoantibodies are elevated in a subset of patients with Chronic Fatigue Syndrome (CFS). Elevated autoantibodies in CFS correlate with elevated IgG1-3 subclass levels, thyreoperoxidase and ANA antibodies and T cell activation. In … Continue reading →

Posted in News | Tagged , , , , , , , | Comments Off on Elevated autoantibodies found in CFS subgroup